Since December 2019, a novel coronavirus (nCoV) of animal origin started infecting humans, initiating a severe outbreak in China. This virus, named "Severe Acute Respiratory Syndrome-related Coronavirus 2" (SARS-CoV-2), can cause a severe and even fatal respiratory disease, called Coronavirus disease-19 (COVID-19), and lead to acute respiratory distress syndrome (ARDS). The virus is highly contagious and transmission occurs presumably via airborne droplets, and fecal-oral route ([@bib25]). SARS-CoV-2 belongs to the genus *Betacoronavirus* of the large family of *Coronaviridae* ([@bib2]). This genus comprises mainly vertebrate respiratory viruses, including HCoV-OC43, which is responsible for 10% of common colds ([@bib14]), and SARS, the cause of an epidemic in 2003 with over 8000 infected individuals in 30 countries ([@bib6]). The SARS-CoV-2 genome has now been sequenced: its close similarity to SARS suggests that it has emerged from the same reservoir, namely bats ([@bib26]).

The SARS-CoV-2 spike protein (S) is the main molecule present at the surface of the virion. This large glycoprotein assembles in trimers that form a crown-like structure on the envelope which gives this virus family its name (corona = crown) ([Fig. 1](#fig1){ref-type="fig"} ). The spike protein is a multifunctional protein that contributes to host receptor binding, cell tropism and pathogenesis. It acts by binding host receptors on target cells, inducing endocytosis of virion particle, and then catalyzes the fusion between host and viral membranes, allowing penetration of the virus genome into host cytoplasm. It is also the major target for the host immune system, adding selective pressure to this complex machinery. The angiotensin converting enzyme II (ACE2) is a known cell receptor for SARS in human and bats, and is also used by SARS-CoV-2 ([@bib26]). We suggest that SARS-CoV-2 may also use integrins as cell receptors in one or more host species, binding to them through a conserved RGD (403--405: Arg-Gly-Asp) motif that is present in the receptor-binding domain of the spike proteins of all SARS-CoV-2 sequences analyzed to date ([Fig. 2](#fig2){ref-type="fig"} ). The motif was identified by a PROSITE scan that included motifs with a high probability of occurrence (PDOC00016) ([@bib16]). It is absent from all other coronavirus spike proteins (n = 30) and from all SARS sequences tested (n = 155). The RGD motif is the minimal peptide sequence required for binding proteins of the integrin family, which are commonly used as receptors by many human viruses ([@bib9]). RGD motif integrin-binding is essential for human metapneumovirus (HMPV) ([@bib3]; [@bib18]), human Adenovirus type 2/5 ([@bib19]), human cytomegalovirus (HHV-5) ([@bib5]), Kaposi\'s sarcoma-associated virus (HHV-8) ([@bib9]), Epstein-Barr virus (HHV-4) ([@bib21], p. 2), Rotavirus (RV) ([@bib24]), and Coxsackievirus A9 ([@bib20]). The conservation of the motif and its localization in the receptor-binding region of the SARS-CoV-2 spike protein suggests that integrins may be alternative receptors for this virus. This could broaden cell tropism and potentially affect viral pathogenicity and transmission.Fig. 1Schematic representation of SARS coronavirus virion ([@bib8]), based on cryo-electron microscopy ([@bib15]).Fig. 1Fig. 2Schematic representation of SARS-CoV-2 S-protein with a focus on the receptor-binding domain. The sequences of 12 betacoronavirus were aligned using MAFFT ([@bib11]). The receptor-binding domain and the ACE2 receptor-binding region are colored in blue and light blue, respectively. The RGD motif of SARS-CoV-2 is highlighted in color. Numbers refer to the SARS-CoV-2 spike protein sequence.Fig. 2

In order to bind integrin, the motif must be present at the surface of the protein. To assess the localization of the RGD motif in the spike protein, we have analyzed its 3D model from SWISS-MODEL ([@bib27]). This model was derived from homology modeling of the SARS-CoV-2 spike glycoprotein sequence from UniProt (P0DTC2; SPIKE_WCPV) with the SARS spike glycoprotein 3D structure (PDB [6ACD](pdb:6ACD){#intref0010}) as template ([@bib1]). The RGD motif and other known binding regions were visualized with Jmol, an open-source Java viewer for chemical structures in 3D (<http://www.jmol.org/>).

The SARS-CoV-2 spike glycoprotein RGD lies in the receptor-binding domain (amino acids 319 to 541) ([Fig. 2](#fig2){ref-type="fig"}) at the border of the subdomain (amino acids 437 to 508) that is specifically involved in the binding to human ACE2 ([@bib13]; [@bib22]). In the unbound state, i.e. the "down" or mushroom-like conformation, the SARS-CoV-2 spike glycoprotein RGD motif defines a small loop (restricted to the motif) between two secondary structures, a β-strand and a α-helix, near the surface of the spike protein ([Fig. 3](#fig3){ref-type="fig"} a and b). Structures of SARS-CoV-2 spike proteins bound to ACE2 receptor motif have been recently made available ([@bib12], p. 2; [@bib23]). ACE2 binding induces dramatic conformational changes involving one of the receptor-binding domains of the trimer. This adopts a protruding "up" conformation, exposing the ACE2 binding subdomain, as well as the region containing RGD ([Fig. 3](#fig3){ref-type="fig"}c and d). However, it is difficult to predict from ACE2 binding how an integrin-binding would look like. It could induce a different conformational change of the receptor-binding domain, exposing the RGD motif to integrin binding.Fig. 3A) and B) Model of SARS-CoV-2 structure provided by SWISSMODEL and visualized with Jmol. A) The mushroom-like fold of the model is the classical one in absence of ligand binding. Ligand binding causes a drastic conformational change leading to the protrusion of one of the trimeric binding domains, further exposing the RGD-loop. The receptor-binding domain has been colored in blue, with a focus in light blue on the part binding the receptor ACE2. The RGD motif is colored in red. B) Enlarged view of the receptor-binding domain. The region demonstrated to bind ACE2, as well as the RGD-loops, are located at the surface of the domain even in the absence of ligand. Same colors as in A. C) and D) Model of SARS-CoV-2 structure in the conformational state of ACE2-binding provided by SWISSMODEL and visualized with Jmol. C) The receptor-binding domain of the trimer is in the "up" conformation exposing the RGD motif. Same color as in [Fig. 2](#fig2){ref-type="fig"}; ACE2 is not represented. D) Close-up view of the receptor-binding domain, highlighting the location of the RGD motif at the very surface of the domain. Same colors as in A.Fig. 3

Integrins are heterodimeric cell surface receptors that play roles in cell adhesion, cell migration, and cell signaling processes ([@bib10]). Viral proteins with RGD motifs promote infection by binding integrin heterodimers such as αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α5β1, α8β1 and αIIbβ3 ([@bib9]), activating transducing pathways involving phosphatidylinositol-3 kinase (PI--3K) or mitogen-activate protein kinase (MAPK), which promote virus entry and infection of the host cell. Adenoviruses of serotypes 2 and 5 possess such proteins, as does human metapneumovirus ([@bib3]; [@bib18]). This virus is the closest to SARS-CoV-2 in terms of organ tropism and symptoms, although it mainly affects children. Interestingly, the metapneumovirus protein F\'s RGD motif adopts a fold similar to that of SARS-CoV-2, with a small loop inserted between two secondary structures (in this case two β-sheets) ([@bib4]). Given these apparent similarities, it is plausible that SARS-CoV-2 acquired integrin-binding to promote virus entry into host cells, but experimental proof of this is required. Binding to integrin may play a supplemental role to ACE2 binding, like facilitating endocytosis by signaling through the integrin. Alternatively, the virus could infect different target cells by binding to ACE2 or to integrins.

There are currently few antiviral molecules that are effective against SARS-CoV-2 ([@bib17]) Agents that block integrin binding may provide a promising avenue of research. Known blockers of integrin binding include the antibody natalizumab (a α4β1/β7 integrin antagonist) for the treatment of multiple sclerosis/Crohn\'s disease, the small molecule tirofiban (an αIIbβ3 inhibitor) for the treatment of acute coronary syndrome, as well as inhibitors of αV RGD-binding integrin ([@bib7]). Anti-integrin pharmacotherapy is certainly possible, although no treatment is yet available that prevents virus-integrin binding, suggesting that further research is necessary to neutralize these pathogens.
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